ReviewNatural product reports2021
Metabolomics and genomics in natural products research: complementary tools for targeting new chemical entities.
Review in Natural product reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 144 citations in OpenAlex.
- Pooled it
- Large-scale discovery platform enables identification of peptides targeting drug-resistant candidiasis.Cell reports methods · 2026Article
- Review
- Natural Products and Neuroregeneration: Rethinking Discovery Beyond Bioavailability Through Pseudo-Natural Product Design.Biomedicines · 2026Review
- Endophytic Fungal Metabolites as Modulators of Key Signaling Pathways in Chronic Diseases and Aging.Antibiotics (Basel, Switzerland) · 2026Review
- Lynamicins H-P and Indimicin H: Chlorinated Bisindole Pyrroles from a Marine-DerivedACS omega · 2026Article
- Bridging Discovery, Mechanism, and Application: An Integrated Strategy for Bioactive Natural Products.Molecules (Basel, Switzerland) · 2026Article
- Progress of metabolomics-centric multi-omics research in medicine.iMetaOmics · 2026Review
- The Incredible Potential of Cave Actinobacteria in Finding New Antimicrobials and Bioactive Compounds.Chemistry & biodiversity · 2026Review
- The Computational Revolution in Natural Product Research: A Data-Driven Roadmap for Next-Generation Drug Development.Biology · 2026Review
- Ameliorative Effect of Valeric Acid Against Psychophysiological Chronic Unpredictable Stress.Biomedicines · 2026Article
- 2A peptides enable simplified discovery and heterologous production of fungal bioactive metabolites in Yarrowia lipolytica.Applied microbiology and biotechnology · 2026Article
- Advances in natural product discovery: strategies, technologies, and insights.Natural products and bioprospecting · 2026Review
- Multidimensional mechanisms of natural products in modulating metabolic dysfunction-associated kidney disease: recent advances and future perspectives.Frontiers in pharmacology · 2026Review
- Endophytic actinomycetes as a reservoir of novel chemotherapeutic leads against multidrug-resistant cancer.Frontiers in artificial intelligence · 2026Article
- Anticancer natural products from the Middle East and North Africa: biodiversity, mechanisms, and translational challenges.Frontiers in oncology · 2026Review
- Productive chaos and precision engineering: decoupling discovery from manufacturing to revolutionize plant-inspired therapeutics.Frontiers in plant science · 2026Article
- Molecules to medicine: advances in metabolomics for natural product drug discovery.Current opinion in biotechnology · 2025Review
- Diterpenoids from the genus Croton and their biological activities.Archives of pharmacal research · 2025Review
- Next-generation perspectives on microbially synthesized siderophores: molecular engineering, multi-omics insights, and applications for smart climate-resilient crops.World journal of microbiology & biotechnology · 2025Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Covering: 2010 to 2021Organisms in nature have evolved into proficient synthetic chemists, utilizing specialized enzymatic machinery to biosynthesize an inspiring diversity of secondary metabolites. Often serving to boost competitive advantage for their producers, these secondary metabolites have widespread human impacts as antibiotics, anti-inflammatories, and antifungal drugs. The natural products discovery field has begun a shift away from traditional activity-guided approaches and is beginning to take advantage of increasingly available metabolomics and genomics datasets to explore undiscovered chemical space. Major strides have been made and now enable -omics-informed prioritization of chemical structures for discovery, including the prospect of confidently linking metabolites to their biosynthetic pathways. Over the last decade, more integrated strategies now provide researchers with pipelines for simultaneous identification of expressed secondary metabolites and their biosynthetic machinery. However, continuous collaboration by the natural products community will be required to optimize strategies for effective evaluation of natural product biosynthetic gene clusters to accelerate discovery efforts. Here, we provide an evaluative guide to scientific literature as it relates to studying natural product biosynthesis using genomics, metabolomics, and their integrated datasets. Particular emphasis is placed on the unique insights that can be gained from large-scale integrated strategies, and we provide source organism-specific considerations to evaluate the gaps in our current knowledge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.